| Literature DB >> 33266263 |
David Šilha1, Karolína Švarcová1, Tomáš Bajer2, Karel Královec1, Eliška Tesařová1, Kristýna Moučková2, Marcela Pejchalová1, Petra Bajerová2.
Abstract
Hydrolates obtained via the hydrodistillation and steam distillation of Lavandulaangustifolia Mill., Syzygiumaromaticum L., Foeniculumvulgare Mill., and Laurusnobilis L. were analyzed by gas chromatography with flame ionization detector (GC-FID) and gas chromatography coupled to mass spectrometry (GC-MS). Additionally, the hydrolates were evaluated for antimicrobial activity (disk-diffusion and microdilution method), influence on biofilm formation (Christensen method) and cytotoxicity of concentrated hydrolates against human cell lines (A549) by xCELLigence system. Using chemical analysis, 48, 9, 13 and 33 different components were detected in lavender, clove, fennel and laurel hydrolates, respectively. Lavender hydrolate contained the largest proportion of 1,8-cineol, linalool furanoxide, and linalool. The main components of laurel hydrolate were 1,8-cineol, 4-terpineol and α-terpineol. Fenchone and estragole were the most abundant in fennel hydrolate, and eugenol and eugenyl acetate in clove hydrolate. Concentrated hydrolates showed significant antimicrobial activity. Clove hydrolate was among the most antimicrobially active agents, most preferably against C. albicans, with an inhibition zone up to 23.5 mm. Moreover, concentrated hydrolates did not show any cytotoxic effect again8 st human A549 cells. In the presence of the non-concentrated hydrolates, significantly reduced biofilm formation was observed; however, with concentrated clove hydrolate, there was an increase in biofilm formation, e.g., of A. thereius, A. lanthieri, and A. butzleri. Research shows new findings about hydrolates that may be important in natural medicine or for preservation purposes.Entities:
Keywords: Arcobacter-like bacteria; Foeniculum vulgare; Laurus nobilis; Lavandula angustifolia; Syzygium aromaticum; antimicrobial activity; biofilm formation; distillation; gas chromatography; hydrolates
Mesh:
Substances:
Year: 2020 PMID: 33266263 PMCID: PMC7730011 DOI: 10.3390/molecules25235654
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Comparison of analyses of HSD_SPE and HHD_SPE extracts by means of peaks in chromatograms, identified compounds and three major components, n = 3.
| Hydrolate from | Peaks in Chromatograms | Identified Compounds (Total Rel. Content) | Main Compounds (Rel. Content) | |||
|---|---|---|---|---|---|---|
| HSD_SPE | HHD_SPE | HSD_SPE | HHD_SPE | HSD_SPE | HHD_SPE | |
| Lavender | 186 | 172 | 48 (90.0%) | 48 (93.2%) | 1,8-Cineole (20.6%) | Linalool (23.2%) |
| ( | 1,8-Cineole (19.5%) | |||||
| α-Terpineol (10.4%) | α-Terpineol (13.0%) | |||||
| Bay leaves | 227 | 166 | 33 (78.0%) | 33 (79.4%) | 1,8-Cineol (56.4%) | 1,8-Cineol (54.1%) |
| 4-Terpineol (6.0%) | 4-Terpineol (7.1%) | |||||
| α-Terpineol (5.0%) | α-Terpineol (6.4%) | |||||
| Fennel | 87 | 68 | 13 (84.1%) | 11 (85.1%) | Estragole (37.4%) | Estragole (33.0%) |
| Fenchone 22.5%) | Fenchone (26.5%) | |||||
| Eugenol (5.6%) | ||||||
| Clove | 98 | 80 | 9 (99.3%) | 9 (99.3%) | Eugenol (89.1%) | Eugenol (92.7%) |
| Eugenyl acetate (9.3%) | Eugenyl acetate (5.6%) | |||||
| Chavicol (0.4%) | Chavicol (0.4%) | |||||
HHD_SPE—hydrolate obtained by hydrodistillation and 50× concentrated using solid phase extraction (SPE); HSD_SPE—hydrolate obtained by steam distillation and 50× concentrated using SPE.
List of compounds identified in hydrolate extracts from Lavandula angustifolia Mill.
| CAS | Compound | RI | % of Total Peak Area | |
|---|---|---|---|---|
| HSD_SPE | HHD_SPE | |||
|
| ||||
| 7392-19-0 | Bois de Rose oxide/Linaloyl oxide | 968 | 0.2 | 0.1 |
| 54750-70-8 | ( | 987 | 0.1 | 0.1 |
| 54750-69-5 | ( | 1004 | 0.1 | <0.1 |
| 470-67-7 | 1,4-Cineol | 1014 | <0.1 | <0.1 |
| 470-82-6 | 1,8-Cineole | 1030 | 20.6 | 19.5 |
| 5989-33-3 | ( | 1070 | 11.9 | 7.9 |
| 34995-77-2 | ( | 1086 | 9.1 | 5. 9 |
| 78-70-6 | Linalool | 1101 | 7.9 | 23.2 |
| 29957-43-5 | Hotrienol | 1103 | 0.8 | 0.5 |
| 471-16-9 | Sabinol | 1139 | 0.1 | 0.2 |
| 76-22-2 | Camphor | 1144 | 0.4 | 0.5 |
| --- | Lilac aldehyde isomer (B or C) | 1148 | <0.1 | <0.1 |
| 1786-08-9 | Nerol oxide | 1151 | 0.4 | 0.2 |
| 5986-38-9 | ( | 1154 | <0.1 | <0.1 |
| 513-20-2 | Sabina ketone | 1158 | <0.1 | <0.1 |
| 30460-92-5 | Pinocarvone | 1160 | <0.1 | <0.1 |
| 53447-47-5 | Lilac aldehyde D | 1163 | <0.1 | <0.1 |
| 14009-71-3 | ( | 1169 | 1.3 | 1.1 |
| 39028-58-5 | ( | 1174 | 1.0 | 0.8 |
| 562-74-3 | 4-Terpineol | 1179 | 1.1 | 1.2 |
| 500-02-7 | Cryptone | 1185 | 0.9 | 0.8 |
| 13741-21-4 | 2,6-Dimethyl-3,7-octadiene-2,6-diol | 1190 | 5.9 | 2.2 |
| 98-55-5 | α-Terpineol | 1194 | 10.4 | 13.0 |
| 80-57-9 | Verbenone | 1207 | 0.2 | 0.2 |
| 1197-07-5 | ( | 1219 | <0.1 | <0.1 |
| 106-25-2 | Nerol | 1225 | 0.7 | 0.9 |
| 18675-34-8 | Neodihydrocarveol | 1231 | 5.9 | 4.9 |
| 122-03-2 | Cuminaldehyde | 1240 | 0.1 | 0.1 |
| 106-24-1 | Geraniol | 1252 | 1.0 | 2.3 |
| 51276-33-6 | 2,6-Dimethyl-1,7-octadien-3,6-diol | 1273 | 1.1 | 0.3 |
| 536-60-7 | Cumin alcohol | 1291 | 0.4 | 0.3 |
| 39725-34-3 | 4-Hydroxy-cryptone | 1322 | 0.2 | <0.1 |
| 160152-34-1 | 3-Oxo- | 1336 | 0.1 | <0.1 |
| 7712-46-1 | 8-Hydroxycarvotanacetone | 1427 | <0.1 | <0.1 |
| 26184-88-3 | α-Bisabolol oxide B | 1653 | 0.1 | 0.1 |
| 3790-71-4 | ( | 1684 | 0.2 | 0.2 |
| Others | ||||
| 111-27-3 | Hexyl alcohol | 872 | 0.2 | 0.2 |
| 3391-86-4 | 1-Octen-3-ol | 981 | 0.2 | 0.2 |
| 589-98-0 | 3-Octanol | 999 | 0.1 | 0.1 |
| 106-68-3 | 3-Octanone | 985 | 0.8 | 0.9 |
| --- | Cymene isomer | 1022 | <0.1 | <0.1 |
| 1073-11-6 | Lavender lactone | 1035 | 0.8 | 2.0 |
| 1604-28-0 | 6-Methyl-3,5-heptadien-2-one | 1103 | 0.6 | 0.7 |
| 24903-95-5 | Nopinone | 1137 | 0.2 | 0.1 |
| 97-53-0 | Eugenol | 1351 | 0.5 | 1.3 |
| 91-64-5 | Coumarin | 1432 | 3.6 | 0.8 |
| 17092-92-1 | Dihydroactinidiolide | 1524 | <0.1 | <0.1 |
| 531-59-9 | 7-Methoxycoumarin (Hernianin) | 1720 | 0.2 | <0.1 |
HHD_SPE—hydrolate obtained by hydrodistillation and 50× concentrated using solid phase extraction (SPE); HSD_SPE—hydrolate obtained by steam distillation and 50× concentrated using SPE; RI—retention index relative to n-alkanes on SLB-5ms capillary column.
List of compounds identified in hydrolate extracts from Laurus nobilis L.
| CAS | Compound | RI | % of Total Peak Area | |
|---|---|---|---|---|
| HSD_SPE | HHD_SPE | |||
|
| ||||
| 470-67-7 | 1,4-Cineol | 1014 | <0.1 | <0.1 |
| 470-82-6 | 1,8-Cineol | 1030 | 56.4 | 54.0 |
| 78-70-6 | Linalool | 1099 | 0.3 | 0.5 |
| 29957-43-5 | Hotrienol | 1101 | <0.1 | <0.1 |
| 36262-12-1 | Dehydrosabina ketone | 1120 | 0.1 | 0.1 |
| 471-16-9 | Sabinol | 1136 | <0.1 | <0.1 |
| 1786-08-9 | Nerol oxide | 1151 | <0.1 | <0.1 |
| 513-20-2 | Sabina ketone | 1157 | 0.5 | 0.6 |
| 30460-92-5 | Pinocarvone | 1160 | 0.4 | 0.3 |
| 562-74-3 | 4-Terpineol | 1178 | 6.0 | 7.1 |
| 13741-21-4 | 2,6-Dimethyl-3,7-octadiene-2,6-diol | 1189 | 0.7 | 0.4 |
| 98-55-5 | α-Terpineol | 1193 | 5.0 | 6.4 |
| 80-57-9 | Verbenone | 1207 | <0.1 | <0.1 |
| 99-48-9 | Carveol | 1218 | 0.2 | 0.4 |
| 18679-48-6 | 2-Hydroxy-1,8-cineole | 1225 | 0.4 | 0.5 |
| 22626-43-3 | cis- | 1228 | 0.5 | 0.8 |
| 494-99-5 | Homoveratrole | 1236 | <0.1 | <0.1 |
| 122-03-2 | Cuminaldehyde | 1240 | <0.1 | <0.1 |
| 51276-33-6 | 2,6-Dimethyl-1,7-octadien-3,6-diol | 1272 | 0.4 | 0.2 |
| 536-60-7 | Cumin alcohol | 1288 | 0.7 | 1.3 |
| 89-83-8 | Thymol | 1298 | 0.2 | 0.1 |
| 22539-72-6 | 1328 | 0.2 | 0.2 | |
| Others | ||||
| 100-52-7 | Benzaldehyde | 960 | <0.1 | <0.1 |
| 110-93-0 | 6-Methyl-5-hepten-2-one | 985 | <0.1 | 0.2 |
| 1073-11-6 | Lavender lactone | 1037 | <0.1 | 0.1 |
| 6090-09-1 | Limona ketone | 1130 | <0.1 | <0.1 |
| 76-49-3 | Bornyl acetate | 1283 | <0.1 | <0.1 |
| 81781-24-0 | 1,3,3-Trimethyl-2-oxabicyclo[2.2.2]octan-5-yl acetate | 1337 | 1.0 | 1.2 |
| 97-53-0 | Eugenol | 1350 | 2.2 | 2.4 |
| 57709-95-2 | 1,3,3-Trimethyl-2-oxabicyclo[2.2.2]octan-6-yl acetate | 1357 | 0.1 | 0.1 |
| 121-33-5 | Vanilin | 1393 | 0.5 | 0.3 |
| 93-15-2 | Methyleugenol | 1399 | 1.8 | 1.7 |
| 17092-92-1 | Dihydroactinidiolide | 1524 | 0.2 | <0.1 |
HHD_SPE—hydrolate obtained by hydrodistillation and 50× concentrated using solid phase extraction (SPE); HSD_SPE—hydrolate obtained by steam distillation and 50× concentrated using SPE; RI—retention index relative to n-alkanes on SLB-5ms capillary column.
List of compounds identified in hydrolate extracts from Foeniculum vulgare Mill.
| % of Total Peak Area | ||||
|---|---|---|---|---|
| CAS | Compound | RI | HSD_SPE | HHD_SPE |
| 142-62-1 | Capronic acid | 982 | 0.2 | n.i. |
| 470-82-6 | 1,8-Cineol | 1030 | 2.8 | 3.8 |
| 122-78-1 | Phenylacetaldehyde | 1042 | 0.1 | n.i. |
| 1195-79-5 | Fenchone | 1086 | 22.5 | 26.5 |
| 78-70-6 | Linalool | 1099 | 0.3 | 0.2 |
| 76-22-2 | Camphor | 1144 | 0.7 | 0.9 |
| 140-67-0 | Estragole | 1196 | 37.4 | 33.0 |
| 99-48-9 | Carveol | 1218 | 2.6 | 2.3 |
| 99-49-0 | Carvone | 1242 | 2.2 | 2.3 |
| 123-11-5 | 1253 | 5.2 | 5.5 | |
| 97-53-0 | Eugenol | 1350 | 2.5 | 5.6 |
| 93-28-7 | Eugenyl acetate | 1513 | 0.8 | 1.0 |
| 1963-36-6 | 1567 | 7.1 | 4.0 | |
HHD_SPE—hydrolate obtained by hydrodistillation and 50× concentrated using solid phase extraction (SPE); HSD_SPE—hydrolate obtained by steam distillation and 50× concentrated using SPE; RI—retention index relative to n-alkanes on SLB-5ms capillary column.
List of compounds identified in hydrolate extracts from Syzygium aromaticum L.
| CAS | Compound | RI | % of Total Peak Area | |
|---|---|---|---|---|
| HSD_SPE | HHD_SPE | |||
| 97-53-0 | Eugenol | 1360 | 89.1 | 92.7 |
| 93-28-7 | Eugenyl acetate | 1516 | 9.4 | 5.6 |
| 501-92-8 | Chavicol | 1253 | 0.4 | 0.4 |
| 121-33-5 | Vanilin | 1393 | 0.3 | 0.4 |
| 458-36-6 | Coniferyl aldehyde | 1727 | 0.2 | 0.2 |
| 119-36-8 | Methyl salicylate | 1189 | <0.1 | <0.1 |
| 87-44-5 | ( | 1417 | <0.1 | <0.1 |
| 6753-98-6 | α-Caryophyllene | 1451 | <0.1 | <0.1 |
| 120-51-4 | Benzyl benzoate | 1764 | <0.1 | <0.1 |
HHD_SPE—hydrolate obtained by hydrodistillation and 50× concentrated using solid phase extraction (SPE); HSD_SPE—hydrolate obtained by steam distillation and 50× concentrated using SPE; RI—retention index relative to n-alkanes on SLB-5ms capillary column.
Antimicrobial activity of hydrolates concentrated by SPE on Arcobacter-like strains—mean inhibition zones in mm (including disc 6 mm in diameter) ± standard deviation and minimal inhibitory/bactericidal concentrations in %, n = 4.
|
| IZ | HHD_SPE | 9.5 ± 0.3 | 8.8 ± 0.3 | 12.8 ± 0.3 | 8.3 ± 0.5 | 8.0 ± 0 | 11.3 ± 1.0 | 9.0 ± 0.8 | 11.5 ± 0.3 |
| HSD_SPE | 10.8 ± 0.3 | 13.5 ± 0.6 | 10.5 ± 0.3 | 9.5 ± 0.9 | 11.5 ± 0.1 | 11.8 ± 0.3 | 10.3 ± 0.5 | 13.3 ± 0.9 | ||
| MIC/ | HHD_SPE | 0.4/0.8 | 0.8/0.8 | 0.8/1.6 | 0.8/0.8 | 0.8/0.8 | 0.8/0.8 | 0.4/0.4 | 0.8/1.6 | |
| HSD_SPE | 0.4/0.4 | 0.4/0.8 | 1.6/1.6 | 0.4/0.8 | 0.4/0.4 | 0.4/0.8 | 0.4/0.4 | 0.4/0.8 | ||
|
| IZ | HHD_SPE | 7.8 ± 0.2 | 9.0 ± 0.8 | 10.5 ± 0.9 | 9.8 ± 0 | 8.5 ± 1.3 | 10.8 ± 0.5 | 7.8 ± 0.5 | 12.0 ± 0.1 |
| HSD_SPE | 10.8 ± 0 | 10.8 ± 0.5 | 10.8 ± 0.9 | 10.0 ± 0.2 | 10.0 ± 0.8 | 11.8 ± 0 | 10.3 ± 0.3 | 11.3 ± 0.5 | ||
| MIC/ | HHD_SPE | 1.6/1.6 | 3.1/3.1 | 1.6/3.1 | 0.8/0.8 | 1.6/1.6 | 1.6/1.6 | 0.8/0.8 | 1.6/1.6 | |
| HSD_SPE | 0.8/1.6 | 1.6/3.1 | 1.6/1.6 | 0.4/0.8 | 0.8/0.8 | 0.8/1.6 | 0.4/0.4 | 0.8/0.8 | ||
|
| IZ | HHD_SPE | 8.0 ± 0.2 | 9.0 ± 0.8 | 9.0 ± 0 | 9.5 ± 0.3 | 9.5 ± 0.3 | 11.3 ± 0.3 | 9.0 ± 0.3 | 10.8 ± 0 |
| HSD_SPE | 10.5 ± 0.3 | 9.5 ± 0.6 | 14.0 ± 0.8 | 10.3 ± 0.3 | 10.0 ± 0.3 | 10.5 ± 0.6 | 12.5 ± 0.7 | 13.3 ± 0.6 | ||
| MIC/ | HHD_SPE | 1.6/1.6 | 1.6/1.6 | 1.6/3.1 | 0.8/1.6 | 0.8/1.6 | 1.6/3.1 | 1.6/3.1 | 1.6/1.6 | |
| HSD_SPE | 0.8/1.6 | 0.8/1.6 | 0.8/1.6 | 0.8/1.6 | 0.8/1.6 | 1.6/3.1 | 1.6/1.6 | 0.8/0.8 | ||
|
| IZ | HHD_SPE | 10.5 ± 0.3 | 12.0 ± 0.9 | 13.0 ± 0.6 | 10.5 ± 0.3 | 14.3 ± 0.5 | 12.0 ± 0.6 | 12.0 ± 0.9 | 14.8 ± 0.5 |
| HSD_SPE | 12.5 ± 0.7 | 13.5 ± 0.4 | 14.5 ± 0.3 | 12.5 ± 0.3 | 16.5 ± 0.3 | 12.8 ± 0.7 | 11.0 ± 0.3 | 15.5 ± 0.7 | ||
| MIC/ | HHD_SPE | 0.1/0.1 | 0.2/0.2 | 0.8/0.8 | 0.2/0.2 | 0.4/0.4 | 0.4/0.4 | 0.2/0.2 | 0.4/0.4 | |
| HSD_SPE | 0.1/0.1 | 0.1/0.1 | 0.8/0.8 | 0.1/0.1 | 0.1/0.1 | 0.4/0.4 | 0.1/0.1 | 0.2/0.4 | ||
|
| IZ | 8.0 ± 0.8 | 7.7 ± 0.5 | 7.7 ± 0.5 | 8.0 ± 0.8 | 7.0 ± 0.8 | 6.7 ± 0.5 | 8.3 ± 0.5 | 8.0 ± 0.8 | |
| MIC/MBC | 3.1/6.3 | 3.1/6.3 | 3.1/6.3 | 1.6/3.1 | 3.1/3.1 | 3.1/3.1 | 1.6/3.1 | 3.1/3.1 | ||
HHD_SPE—hydrolate obtained by hydrodistillation and 50× concentrated using solid phase extraction (SPE); HSD_SPE—hydrolate obtained by steam distillation and 50× concentrated using SPE; Control—solvent without active compounds; IZ—inhibition zone; MIC—minimal inhibitory concentration; MBC—minimal bactericidal concentration; Ab—A. butzleri; Ac—A. cryaerophilus; Al—A. lanthieri; As—A. skirrowii; At—A. thereius.
Antimicrobial activity of hydrolates concentrated by SPE on selected microorganisms—mean inhibition zones in mm (including disc 6 mm in diameter) ± standard deviation or minimal inhibitory concentrations in %, n = 4.
|
| IZ | HHD_SPE | 8.5 ± 0.7 | 7.5 ± 0.6 | 8.5 ± 0.4 | 8.8 ± 0.5 | 6.0 ± 0 |
| HSD_SPE | 8.3 ± 0.5 | 9.5 ± 0.3 | 10.5 ± 0.3 | 9.0 ± 0.3 | 6.0 ± 0 | ||
| MIC/ | HHD_SPE | 1.6/3.1 | 3.1/3.1 | 1.6/3.1 | 1.6/3.1 | 6.3/6.3 | |
| HSD_SPE | 1.6/3.1 | 1.6/3.1 | 1.6/1.6 | 1.6/3.1 | 6.3/6.3 | ||
|
| IZ | HHD_SPE | 10.8 ± 0.9 | 9.3 ± 0.9 | 11.0 ± 0.8 | 11.3 ± 0.5 | 10.5 ± 0.6 |
| HSD_SPE | 11.3 ± 0.7 | 15.0 ± 0.1 | 11.5 ± 0.8 | 11.5 ± 0.3 | 11.8 ± 0.7 | ||
| MIC/ | HHD_SPE | 3.1/6.3 | 3.1/6.3 | 3.1/3.1 | 1.6/3.1 | 1.6/3.1 | |
| HSD_SPE | 3.1/6.3 | 1.6/3.2 | 1.6/3.1 | 1.6/3.1 | 1.6/3.1 | ||
|
| IZ | HHD_SPE | 9.5 ± 0.3 | 11.0 ± 0.8 | 10.3 ± 0.7 | 10.3 ± 0.7 | 9.8 ± 0.9 |
| HSD_SPE | 9.5 ± 0.6 | 12.3 ± 0.5 | 11.5 ± 0.9 | 10.5 ± 0.9 | 13.3 ± 0.9 | ||
| MIC/ | HHD_SPE | 1.6/1.6 | 6.3/12.5 | 1.6/3.1 | 3.1/6.3 | 1.6/3.1 | |
| HSD_SPE | 1.6/1.6 | 6.3/6.3 | 3.1/6.3 | 1.6/3.1 | 0.4/0.8 | ||
|
| IZ | HHD_SPE | 15.8 ± 0.7 | 15.3 ± 0.3 | 11.3 ± 0.1 | 13.5 ± 0.7 | 14.8 ± 0.4 |
| HSD_SPE | 15.5 ± 0.9 | 18.8 ± 0.9 | 12.8 ± 0.7 | 14.0 ± 0.8 | 23.5 ± 0.7 | ||
| MIC/ | HHD_SPE | 0.4/0.4 | 0.8/0.8 | 0.8/1.6 | 3.1/6.3 | 6.3/6.3 | |
| HSD_SPE | 0.4/0.8 | 0.4/0.8 | 0.4/0.8 | 1.6/3.1 | 1.6/3.1 | ||
|
| IZ | 7.3 ± 0.5 | 9.0 ± 0.8 | 8.7 ± 0.5 | 8.0 ± 0 | 6.3 ± 0.5 | |
| MIC/MBC | 12.5/12.5 | 12.5/12.5 | 3.1/6.3 | 6.3/12.5 | 6.3/12.5 | ||
HHD_SPE—hydrolate obtained by hydrodistillation and 50× concentrated using solid phase extraction (SPE); HSD_SPE—hydrolate obtained by steam distillation and 50× concentrated using SPE; Control—solvent without active compounds; IZ—inhibition zone; MIC—minimal inhibitory concentration; MBC—minimal bactericidal concentration; Sa—S. aureus; Ef—E. faecalis; Pa—P. aeruginosa; Ec—E. coli; Ca—C. albicans.
Testing the effectiveness of antibiotics and antifungals (mean inhibition zones in mm, including disc 6 mm in diameter ± standard deviation), n = 4.
| AMP | CIP | DA | E | TE | FCA | |
|---|---|---|---|---|---|---|
| 6.0 ± 0 | 43.5 ± 2.1 | 7.5 ± 0.7 | 37.5 ± 0.7 | 31.5 ± 2.1 |
| |
| 6.0 ± 0 | 34.5 ± 0.7 | 6.0 ± 0 | 23.0 ± 0 | 16.0 ± 0 |
| |
| 6.0 ± 0 | 39.0 ± 1.4 | 6.0 ± 0 | 29.0 ± 1.4 | 24.0 ± 1.4 |
| |
| 6.0 ± 0 | 25.0 ± 0 | 6.0 ± 0 | 31.5 ± 0.7 | 27.5 ± 0.7 |
| |
| 6.0 ± 0 | 36.5 ± 0.7 | 6.0 ± 0 | 30.5 ± 0.7 | 29.0 ± 1.4 |
| |
| 6.0 ± 0 | 37.0 ± 1.4 | 6.0 ± 0 | 22.0 ± 2.8 | 17.5 ± 0.7 |
| |
| 6.0 ± 0 | 41.0 ± 1.4 | 23.0 ± 2.8 | 30.0 ± 0 | 34.0 ± 2.8 |
| |
| 6.0 ± 0 | 32.5 ± 0.7 | 35.5 ± 0.7 | 11.0 ± 0 | 35.0 ± 0 |
| |
| 27.0 ± 0 | 25.5 ± 0.5 | 27.0 ± 1.4 | 28.0 ± 2.8 | 14.5 ± 0.7 |
| |
| 13.0 ± 0 | 22.0 ± 0 | 7.0 ± 0 | 17.5 ± 0.7 | 29.0 ± 1.4 |
| |
| 6.0 ± 0 | 34.0 ± 1.4 | 6.0 ± 0 | 8.5 ± 0.7 | 13.5 ± 0.7 |
| |
| 6.0 ± 0 | 31.0 ± 1.4 | 6.0 ± 0 | 9.5 ± 0.7 | 20.5 ± 0.7 |
| |
|
|
|
|
|
| 16.0 ± 1.4 |
AMP—ampicillin, CIP—ciprofloxacin, DA—clindamycin, E—erythromycin, TE—tetracycline, FCA—fluconazole, n.t.—not tested.
Figure 1Biofilm formation in the presence of non-concentrated hydrolates (a) and concentrated hydrolates (b). Bars represent standard deviation, n = 3. HHD—hydrolate obtained by hydrodistillation; HSD—hydrolate obtained by steam distillation; HHD_SPE—hydrolate obtained by hydrodistillation and 50× concentrated using solid phase extraction (SPE); HSD_SPE—hydrolate obtained by steam distillation and 50× concentrated using SPE. Red lines—biofilm formation of strains in water (a), biofilm formation of strains in extraction solvent (b); values above/below the red lines—increased/reduced biofilm formation due to hydrolate presence.
Figure 2Dynamic monitoring of cytotoxic response to different concentrations of the hydrolates concentrated by SPE. A549 cells were treated with selected concentrations of (a) lavender, (b) fennel, (c) bay leaves and (d) clove concentrated hydrolates. Cells treated with 0.1%, 0.4% and 0.8% ethanol were used as vehicle control and 5% DMSO treated cells were as positive control. Arrow showing time-point of treatment. Cell index values over 72 consecutive treatment hours were normalized to the time point of treatment.